Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

In the latest quarter, 15 analysts provided ratings for BioNTech (NASDAQ:BNTX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed partial clinical hold on Phase 3 study of BNT316/ONC-392 (gotistobart) in ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence ...

Atomi Financial Group Inc. bought a new position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) during the 3rd quarter, ...

Truist Financial Corp lowered its position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 4.1% in the second quarter ...

Pfizer (NYSE: PFE) was a stock on the move Wednesday, and not because of any news generated by the healthcare company. Reports of a meeting between Pfizer's leader and an activist investor ...

Shares of NASDAQ BNTX opened at $117.47 on Monday. The business has a 50-day simple moving average of $99.38 and a two-hundred day simple moving average of $92.98. BioNTech has a 52 week low of ...